Jakarta – Saturday, 30 October 2021, refer to the Decision of Chairman of Bapepam dan LK Nomor: KEP-346/BL/2011 dated 05 July 2011 regulation No.X.K.2 about the Submission of Periodic Financial Statements of Issuers or Public Companies and the financial services authority REGULATION Number: 7/POJK.04/2018 dated 25 April 2018 on the Submission of Reports through the Electronic Reporting System for Issuers or Public Companies and in accordance with the Regulations of the Stock Exchange Jakarta stock number: KEP-306/BEJ/07-2004 dated July 19, 2004, on the Regulation No. I-E part III “newsletter”, PT Mustika Ratu Tbk (“the Company”) and its subsidiaries have been loading the Consolidated Financial Statements for the Third Quarter of 2021, which is not audited and ended on 30 September 2021 on the website of the Indonesia Stock Exchange and the Company’s website.
Baca Juga : Dubai Expo : MRAT Entering Middle East
Through the development strategy of the two divisions, Beauty & Personal Care and Herbal medicine & Health Care, the company recorded net sales in the Third Quarter of 2021 Rp. 255,9 billion and increased by Rp. 33,6 billion of 15,13% in comparison with the Third Quarter of 2020 amounted to Rp. 222,27 billion.
The increase in net sales was driven by higher sales in the sector of health products by 54,62% and increased consumption of health drinks & herbal medicine which has increased by 30,38%.
Successful MRAT Strategy Generate Net Sales
Operationally, the company obtained an operating profit in the third quarter of 2021 Rp. 7,26 billion, an increase of Rp. 166 million or 2,34% compared to the third quarter of 2020 amounted to Rp. 7,094 billion.
The Management of PT Mustika Ratu Tbk (MRAT) is optimistic about the development of the distribution channel and is supported by the consistent transformation of the company on all fronts, which will increase sales and profits for the year.
